Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: Results of a prospective study in Japan

International Journal of Hematology

Volumn 92, Issue 1, 2010, Pages 111-117

  Nagai, Tadashi ^a   Takeuchi, Jin ^b   Dobashi, Nobuaki ^c   Kanakura, Yuzuru ^d   Taniguchi, Shuichi ^e   Ezaki, Koji ^f   Nakaseko, Chiaki ^g   Hiraoka, Akira ^h   Okada, Masaya ⁱ   Miyazaki, Yasushi ^j   Motoji, Toshiko ^k   Higashihara, Masaaki ^l   Tsukamoto, Norifumi ^m   Kiyoi, Hitoshi ⁿ   Nakao, Shinji ^o   Shinagawa, Katsuji ^p   Ohno, Ryuzo ^q   Naoe, Tomoki ⁿ   Ohnishi, Kazunori ^r   Usui, Noriko ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY HOSPITAL   (Japan)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

^e TORANOMON HOSPITAL   (Japan)

^f FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^g CHIBA UNIVERSITY HOSPITAL   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE HOSPITAL   (Japan)

^j NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^k TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^l KITASATO UNIVERSITY HOSPITAL   (Japan)

^m GUNMA UNIVERSITY HOSPITAL   (Japan)

ⁿ NAGOYA UNIVERSITY HOSPITAL   (Japan)

^o KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^p OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^q AICHI CANCER CENTER HOSPITAL   (Japan)

^r HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chronic myeloid leukemia; Chronic phase; Imatinib; Newly diagnosed

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EVENT FREE SURVIVAL; FEMALE; FEVER; GASTROENTERITIS; HUMAN; JAPAN; KAPLAN MEIER METHOD; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RHINOPHARYNGITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; CHILD; DRUG TOXICITY; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955172949     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0621-x     Document Type: Article

References (16)

1. BJ Druker S Tamura E Buchdunger S Ohno GM Segal S Fanning, et al. 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561 566 10.1038/nm0596-561 1:CAS:528: DyaK28Xislyhs70%3D 8616716
2. BJ Druker M Talpaz DJ Resta B Peng E Buchdunger JM Ford, et al. 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Eng J Med 344 1031 1037 10.1056/NEJM200104053441401 1:CAS:528:DC%2BD3MXivFGnu70%3D
3. SG O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes, et al. 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Eng J Med 348 994 1004 10.1056/NEJMoa022457
4. H Kantarjian C Sawyers A Hochhaus F Guilhot C Schiffer C Gambacorti-Passerini, et al. 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Eng J Med 346 645 652 10.1056/NEJMoa011573 1:CAS:528:DC%2BD38XhsFOjsr8%3D
5. H de Lavallade JF Apperley JS Khorashad D Milojkovic AG Reid M Bua, et al. 2008 Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis J Clin Oncol 26 3358 3363 10.1200/JCO.2007.15.8154 18519952
6. M Talpaz RT Silver BJ Druker JM Goldman C Gambacorti-Passerini F Guilhot, et al. 2002 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 1928 1937 10.1182/blood.V99.6.1928 1:CAS:528:DC%2BD38XitF2nt74%3D 11877262
7. CL Sawyers A Hochhaus E Feldman JM Goldman CB Miller OG Ottmann, et al. 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 3530 3539 10.1182/blood.V99.10.3530 1:CAS:528: DC%2BD38XjvVGns78%3D 11986204
8. Y Morishima M Ogura M Nishimura F Yazaki M Bessho H Mizoguchi, et al. 2004 Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study Int J Hematol 80 3 261 266 10.1532/IJH97.04074 1:CAS:528:DC%2BD2cXhtVShtLvK 15540902
9. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Eng J Med 355 2408 2417 10.1056/NEJMoa062867 1:CAS:528: DC%2BD28Xht12ntrzM
10. E Matsuo Y Miyazaki C Tsutsumi Y Inoue R Yamasaki T Hata, et al. 2007 Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in Nagasaki prefecture, Japan Int J Hematol 85 2 132 139 10.1532/IJH97.06157 1:CAS:528:DC%2BD2sXjvV2rtLo%3D 17321991
11. I Ishikawa C Kato H Harigae T Sugawara Y Tomiya M Yamada, et al. 2006 Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia Tohoku J Exp Med 210 4 355 363 10.1620/tjem.210.355 1:CAS:528:DC%2BD2sXkslGjtw%3D%3D 17146202
12. A Horikoshi K Takei S Sawada 2003 Effects of lower doses of imatinib to CML patients Leuk Res 27 1167 10.1016/S0145-2126(03)00101-2 12921957
13. M Sakai Y Miyazaki E Matsuo Y Moriuchi T Hata T Fukushima, et al. 2009 Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group Int J Hematol 89 3 319 325 10.1007/s12185-009-0263-z 1:CAS:528:DC%2BD1MXkt1yhur4%3D 19266256
14. Y Kanda S Okamoto T Tauchi M Kizaki K Inokuchi M Yabe, et al. 2008 Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter? Am J Hematol 83 11 835 839 10.1002/ajh.21274 1:CAS:528:DC%2BD1cXhsVyntLnO 18785644
15. M Kizaki S Okamoto T Tauchi H Tanaka M Tanimoto K Inokuchi, et al. 2008 Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH Int J Hematol 88 4 409 417 10.1007/s12185-008-0186-0 18953513
16. J Sugita J Tanaka M Kurosawa T Fukuhara S Hashino E Torimoto, et al. 2008 Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group Eur J Haematol 80 2 160 163 1:CAS:528: DC%2BD1cXivFahsbc%3D 18028432